Diane Burt
Psychiatric/Mental Health · Bridgeton, NJNPI 1043229883
Payments from drug & device makers
Across 732 payments — averaging $110.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$73K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Axsome Therapeutics, Inc.$798
- Otsuka America Pharmaceutical, Inc.$787
- Alkermes, Inc.$595
- Lundbeck LLC$564
- plus $4K from 22 others
What the payments were for
- Speaking & faculty fees$68,88885%
- Travel & lodging$1,7552%
- Food & beverage$10,53213%
- Education$730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 231 | $73,367 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 88 | $1,551 |
| Axsome Therapeutics, Inc. | 31 | $798 |
| Otsuka America Pharmaceutical, Inc. | 50 | $787 |
| Alkermes, Inc. | 37 | $595 |
| Lundbeck LLC | 58 | $564 |
| Neurocrine Biosciences, Inc. | 30 | $478 |
| Teva Pharmaceuticals USA, Inc. | 34 | $459 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $381 |
| Tris Pharma Inc | 20 | $273 |
| Bausch Health US, LLC | 18 | $266 |
| E.r. Squibb & Sons, L.L.C. | 6 | $262 |
| Neos Therapeutics, LP | 17 | $225 |
| Vanda Pharmaceuticals Inc. | 15 | $205 |
| Sunovion Pharmaceuticals Inc. | 9 | $164 |
| Corium, LLC | 10 | $158 |
| Avanir Pharmaceuticals, Inc. | 10 | $132 |
| Noven Therapeutics, LLC | 7 | $99 |
| Merck | 7 | $96 |
| Almatica Pharma LLC | 6 | $95 |
| Ironshore Pharmaceuticals Inc. | 6 | $81 |
| Adlon Therapeutics L.p. | 5 | $69 |
| Johnson & Johnson | 2 | $30 |
| Sage Therapeutics, LLC | 2 | $29 |
| USWM, LLC | 2 | $28 |
| Eisai Inc. | 2 | $27 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| OWP Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$81,248 in reported general payments places this provider in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 62 | $125,491 |
| RexultiBrexpiprazole | 18 | $55,842 |
| TrintellixVortioxetine Hydrobromide | 44 | $40,679 |
| VyvanseLisdexamfetamine Dimesylate | 36 | $13,724 |
| Lisdexamfetamine Dimesylate | 40 | $9,789 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 141 | $4,739 |
| Aripiprazole | 33 | $2,957 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 40 | $2,880 |
| Quetiapine Fumarate | 83 | $2,598 |
| Paliperidone ErPaliperidone | 14 | $2,311 |
| Alprazolam | 316 | $2,126 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 14 | $2,088 |
| Lurasidone Hcl | 14 | $1,655 |
| Oxcarbazepine | 21 | $1,488 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 19 | $1,480 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $73,367 | $125,49162 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $787 | $55,84218 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $381 | $54,40380 claims |
| Almatica Pharma LLCSertraline Hcl | $95 | $32534 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Other psychiatric/mental health in Bridgeton
- Ubong UdofiaMarlton$407K
- Anthony DimuraRed Bank$130K
- Amy PinsenNewton$111K
- Aaron SpectorMarlton$100K
- Fiorella ParadisiSparta$84K
- Alta ManessHackensack$75K
- Laura LeahySewell$41K
- Linda WinfulMontclair$40K
- Marisa SavicOradel$38K
- Tyreasea Johnson MasonHaddon Township$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.